Romuald Corbau
Technik-/Wissenschafts-/F&E-Leiter bei ADVERUM BIOTECHNOLOGIES, INC.
Profil
Romuald Corbau is currently the Chief Scientific Officer at Adverum Biotechnologies, Inc. He previously held the same position at Freeline Therapeutics Holdings Plc from 2020 to 2021.
Additionally, he served as the Chief Scientific Officer at GenEdit, Inc. Dr. Corbau is a graduate of Université des Sciences et Technologies de Lille.
Aktive Positionen von Romuald Corbau
| Unternehmen | Position | Beginn |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 29.01.2024 |
Ehemalige bekannte Positionen von Romuald Corbau
| Unternehmen | Position | Ende |
|---|---|---|
| FREELINE THERAPEUTICS HOLDINGS PLC | Technik-/Wissenschafts-/F&E-Leiter | 20.08.2021 |
GenEdit, Inc.
 GenEdit, Inc. Pharmaceuticals: MajorHealth Technology GenEdit, Inc. develops gene therapies and gene editing-based therapeutics. Its proprietary nanoparticles applies for the development of CRISPR-based therapeutics and gene therapy products for a range of genetic diseases. The company was founded by Kunwoo Lee, Niren Murthy, and Hyo Min Park in 2016 and is headquartered in Berkeley, CA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Romuald Corbau
| Université des Sciences et Technologies de Lille | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
GenEdit, Inc.
GenEdit, Inc. Pharmaceuticals: MajorHealth Technology GenEdit, Inc. develops gene therapies and gene editing-based therapeutics. Its proprietary nanoparticles applies for the development of CRISPR-based therapeutics and gene therapy products for a range of genetic diseases. The company was founded by Kunwoo Lee, Niren Murthy, and Hyo Min Park in 2016 and is headquartered in Berkeley, CA. | Health Technology |
